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Abstract
The corpus luteum (CL) is a site of intense angiogenesis. Within a short period, this is followed
either by controlled regression of the microvascular tree in the non-fertile cycle, or maintenance
and stabilisation of the new vasculature a conceptual cycle. The molecular regulation of these
diverse aspects is examined. The CL provides a unique model system in which to study the cellular
and molecular regulation of angiogenesis. Vascular endothelial growth factor (VEGF) has been
found to have a major role in the CL. By targeting its action at specific stages of the luteal phase in
vivo by antagonists, profound inhibitory effects on luteal angiogenesis and function are observed.
Introduction
The corpus luteum (CL) is a site of intense angiogenesis,
the formation of a dense capillary network enabling the
hormone-producing cells to obtain the oxygen, nutrients
and hormone precursors necessary to synthesise and
release large amounts of progesterone required for estab-
lishment and maintenance of early pregnancy. Endothe-
lial cells, once differentiated, normally remain functional
for periods of 2–3 years, but in the CL a non fertile cycle
results in structural luteolysis and these newly formed
blood vessels regress within a matter of weeks. [1]. How-
ever, in a fertile cycle, the life span of the CL, with its
attendant vasculature, is prolonged. Therefore, within a
short period, the CL must accommodate a period of ang-
iogenesis, controlled regression of the vasculature in the
non-fertile cycle, or maintenance of the vasculature. Inves-
tigations of the mechanisms of vascular growth and
regression in this unique situation will provide insights
into the angiogenic process and may lead to new strategies
in treatment of luteal-based infertility and to a method of
'once a month' fertility control.
The molecular and cellular regulation of angiogenesis is
complex with a growing list of potential regulators. In a
previous review we illustrated the importance of inhibit-
ing specific angiogenic factors in vivo to determine
whether a specific factor, or its receptor(s), has a major
role, or is of no physiological significance [2] using angio-
genesis in the CL as an end point. The success of this
approach has been dependent upon two developments.
First, methods to accurately quantify proliferating
endothelial cells on tissue sections have been made possi-
ble by immuocytochemical (ICC) staining for Ki67 or
bromodeoxyuridine (BrdU) incorporation to identify
proliferating cells together with dual staining with mark-
ers for endothelial cells. Secondly, the generation of spe-
cific inhibitors allows selective targeting of individual
factors in the angiogenic pathway in vivo. However, such
advances are dependent upon continued discoveries using
molecular and in vitro techniques. Here, we introduce the
cellular aspects of angiogenesis in the normal cycle, ask
what has been learnt from examining cyclic changes in
some of the potential regulatory factors involved, then
examine the unresolved issues in the divergent processes
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of regulation of luteolysis and luteal rescue. Finally, recent
insights from in vivo manipulation are reviewed.
Normal luteal phase
Angiogenesis in the CL has its origins in the vasculature of
the developing follicle [3]. Blood vessels lying within the
thecal layer are denied entry into the granulosa cell layer
by the presence of the basement membrane. On collapse
of the follicle inwards, the thecal layer, together with its
attendant blood vessels, is situated within the folds of the
granulosa compartment. There is loss of integrity of the
basement membrane, accompanied by extensive tissue re-
modelling, with the commencement of invasion of the
differentiating granulosa lutein cell-containing region by
new blood vessel development from the pre-existing the-
cal vasculature. Variable amounts of blood and plasma
extravasate into the follicular cavity where they form a
fibrin-rich clot [4]. The next few days are associated with a
period of intense angiogenesis with resultant newly
formed microvessels extending throughout the tissue.
Comparison of the proliferation index through the early,
mid- and late luteal phases shows that it is in the early
luteal phase that the most intense angiogenesis is taking
place in all mammals studied to date, e.g., rat [5] sheep [6]
bovine [7], mare [8] marmoset monkey [9], rhesus mon-
key [10] and human [11,12]. Dual staining shows that at
all stages of the luteal phase >80% of the dividing cells in
the CL are endothelial [7-20]. In the mature gland, > 50%
of cells are endothelial, all of the fully differentiated lutein
cells are in contact with the endothelium and the CL has
the highest blood flow of any tissue in the body.
In most tissues, the generation of new blood vessels is fol-
lowed by recruitment of perivascular cells (pericytes), sim-
ilar to vascular smooth muscle cells, to the outer wall of
the vessel to afford stabilisation [13,15]. Recruitment of
pericytes appears to take place rapidly in the CL as they are
detectable in the early luteal phase and the percentage of
vessels with associated pericytes increases as the luteal
phase progresses in the bovine [13] and human CL [14].
Pericytes are also present in the pre-ovulatory follicle. In
the sheep it has been proposed that perivascular cells,
largely pericytes, in the ovulated follicle have an addi-
tional role as lead cells in guiding the blood vessels
towards the former antrum [15]. In addition, in the sheep,
capillary pericytes exhibit a high rate of pericyte prolifera-
tion in the early CL [15]. Further work is required to
address the role of pericytes in early luteal angiogenesis
and in guidance of blood vessels into the CL.
Molecular regulation of luteal angiogenesis
In most tissues, hypoxia is the stimulus for the synthesis
of angiogenic factors [16]. Hypoxia in luteal angiogenesis
may be important at certain stages and more detailed
studies on this question are required. However, there is
substantial evidence that luteal angiogenesis is hormo-
nally regulated by luteinising hormone (LH) as most of
the major potential regulatory factors are produced by the
lutein cells, which respond to changing LH stimulation
[9,17-21].
Vascular endothelial growth factor (VEGF, also known as
vascular permeability factor, VPF) is the major specific
stimulator of endothelial cell proliferation, acting
through two tyrosine kinase receptors, VEGFR-1(flt-1)
and VEGFR-2 (KDR) [16]. The first VEGF to be discovered,
VEGF-A, is the most important in the CL, but some of the
other members of this family [16] may also have a special-
ised role [17]. VEGF production increases in luteinizing
granulosa cells of the ovulatory follicle [18] and is stimu-
lated by addition of human chorionic gonadotrophin
(hCG) to luteinized granulosa cells in culture [19]. In
most species, VEGF mRNA is detected in the new CL in the
granulosa-derived lutein cells, e.g., mouse [20] and
human [21,22]. Several studies have examined whether
changes in expression of angiogenic factors and their
receptors may help explain the diverse changes in luteal
vasculature. In the human, in situ hybridization showed
that VEGF-A mRNA continues to be expressed at a high
level throughout the luteal lifespan [22]. This may serve as
a survival factor for endothelial cells and as a permeability
factor. Other studies provide evidence for a fall in VEGF
mRNA during luteal regression. Using northern blot anal-
ysis, a fall in VEGF expression from the mid- to late luteal
phase was found in human CL [24,25]. In rhesus monkey
CL, RT-PCR studies showed a 2 fold increase in VEGF
expression between the early and mid-luteal phase fol-
lowed by a 2 fold decline from mid- to late [23]. It is pos-
sible that the demonstration of a decline in expression in
the late luteal phase are the result of more regressed spec-
imens being studied [23,24] than the in situ investigation
[22].
In primates, VEGF protein is localised in the hormone-
producing cells of the CL, being highest in the granulosa-
derived cells [4,14,21,23-25]. Similar results were
reported in the equine CL [8]. VEGF is present throughout
the luteal phase becoming less widespread during luteol-
ysis. In apparent contrast, in sheep CL a highly specific
antibody localised VEGF in vascular pericytes but it was
absent from the hormone-producing cells [15].
With respect to VEGF receptors, in situ data for the CL is
limited, probably because of low levels of expression,
although endothelial cells are likely to be the site of
expression [16]. Northern blot analysis and semi quanti-
tative PCR in macaque or human CL [23-25] demon-
strated expression of VEGFR-1 and VEGFR-2 mRNA at all
stages of the luteal phase with a 2–3 fold decline in theReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/88
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late luteal phase. ICC localises VEGFR-1 and VEGFR-2 to
luteal endothelial cells, but also to hormone-producing
cells [21,24,25].
Co-ordination of blood vessel formation and regression
also involves other factors. These include the angiopoie-
tins Ang-1 and Ang-2, which are of particular interest with
respect to regulation of the rapidly-changing luteal vascu-
lature because Ang-1 stimulates stabilisation of blood ves-
sels while Ang-2 causes destabilisation [26]. Ang-2, acting
through its tyrosine kinase receptor Tie-2, aids the action
of VEGF by reducing endothelial contact with the extra
cellular matrix, and hence with adjacent endothelial cell
interactions. In contrast, Ang-1 acts via the same receptor
as a competitive antagonist and enhances the stability of
the newly formed blood vessels by recruiting pericytes
[26]. A potential role for the angiopoeitins in regulating
both luteal angiogenesis and vascular regression at luteol-
ysis was proposed from in situ hybridisation observations
in the rat ovary [26]. On formation of the CL, high levels
of VEGF were expressed uniformly; expression of Ang-2
was more restricted, suggesting an action in serving to
enhance the angiogenic effects of VEGF at certain loci,
while localised expression of Ang-1 may serve to stabilise
the new blood vessels [26]. At luteolysis, VEGF mRNA
decreased and the Ang-2:Ang-1 ratio increased. It was pro-
posed that this change would destabilise vessels in the CL
and lead to vascular regression via apoptosis [26]. Sup-
porting evidence for this attractive scenario has been ten-
tative. In situ hybridization in human CL demonstrated
itense expression of Ang-2 in a small number of endothe-
lial and a few hormone producing cells while Ang-1
expression was low and diffuse [22]. A rise in Ang-2
mRNA expression has been reported using PCR in the
regressing bovine CL [13]. In the rhesus monkey, both
Ang-1 and Ang-2 mRNA rose at the late luteal phase [23].
Perhaps the mechanism by which expression of VEGF and
the angiopoeitins change to induce endothelial cell apop-
tosis differs between species. In those such as the cow in
which luteolysis is brought about by endogenous lute-
olysin, e.g. prostaglandin F2 alpha, a rapid sequence of
molecular and cellular changes may be demonstrated
associated with endothelial cell apoptosis. In primate spe-
cies in which luteolysis is a more protracted process, and
endothelial cell apoptosis is observed for a short time
frame [1], these changes may be obscured.
Many other factors have been suggested to influence luteal
angiogenesis. Estrogens may induce angiogenesis by act-
ing directly on endothelial cells or by inducing angiogenic
factors in other cell types; possible actions of progester-
one, activin A, follistatin and other factors have been dis-
cussed elsewhere [27]. Recently, connective tissue growth
factor (CTGF) has been proposed as a promoter of migra-
tion of endothelial cells in the CL [28]. Insulin like growth
factor binding protein-3 is highly expressed in luteal
endothelial cells and may be involved in determining
accessibility of IGF [29].
Of particular current interest is a novel regulator of ovar-
ian angiogenesis, endocrine gland VEGF (EG-VEGF) iden-
tified from the human ovary and which has been
proposed as a steroidogenic endocrine gland specific ang-
iogenic regulator [30]. Although highest levels are found
in the ovary, testis and adrenal, EG-VEGF is also present at
lower levels in other tissues such as the small intestine,
where its action appears to be in regulating contraction of
gastrointestinal smooth muscle [31]. The sequence was
discovered independently from the small intestine and
named prokineticin-1 [31]. Functionally, EG-VEGF/ prok-
ineticin-1 is similar to VEGF: it induces endothelial cell
proliferation, migration and fenestration of endothelial
cells but the activity seems selective to endocrine glands
[30]. It also induced extensive angiogenesis when deliv-
ered by adenovirus to the mouse ovary, but not in other
tissues [30,32]. EG-VEGF/ prokineticin-1 consists of 86
amino acids. It is structurally distinct from VEGF but dis-
plays an 80% homology to a protein in the venom of the
black mamba snake [30]. EG-VEGF/ prokineticin-1 acts
via G protein-coupled receptors, prokineticin-R1 and
prokineticin-R2 [33].
EG-VEGF mRNA has been reported in rhesus monkey CL,
and RT PCR studies showed an increase as the CL matures
[34], and by in situ hybridization in the human CL [35]. A
factor related to EG-VEGF/prokineticin-1 has also been
discovered and termed Bv8 or prokineticin-2 and is highly
expressed in the testis, but is apparently absent from the
CL [35].
Fenestration of the endothelial cell membrane plays a role
in the high permeability of the ovarian endothelial cells.
The fenestrae are highly permeable to fluid and small sol-
utes and are thought to facilitate the large exchange of
materials between interstitial fluid and plasma associated
with the CL. Since EG-VEGF and VEGF have an additive
response in vitro it is suggested that they may also cooper-
ate in vivo to induce the fenestrated phenotype and to pro-
mote angiogenesis [32], especially as both molecules are
produced in the CL. Studies on the localisation of EG-
VEGF and its receptors in the CL, how it is regulated by LH
and/or hypoxia and in vivo studies to determine role of
EG-VEGF are now required. The idea that there are ang-
iogenic factors exhibiting tissue specificity means that
more specific targeting should be possible than could be
achieved by inhibition of VEGF.
In summary, the approaches described above have pro-
vided strong evidence for the role of various angiogenicReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/88
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factors in the regulation of luteal angiogenesis. Compar-
ing changes in expression ratios at different stages of the
luteal phase has provided an indication of how the diver-
gent changes in the vasculature may be controlled. How-
ever, in most studies in primates, especially in the human
CL, major changes in gene expression of angiogenic fac-
tors or their receptors do not appear to precede vascular
regression. Thus, the molecular regulation of vascular
regression in the CL needs further investigation. Given the
divergent nature of the various stages of the CL lifespan, it
is surprising that more work has not been done on gene
analysis by differential display or micro arrays. Since the
regressive process are likely to involve localised changes in
gene expression by specific cell types, further studies using
in situ hybridization, ICC and specific vascular markers are
required. Such investigations may also benefit from laser
capture techniques.
Pregnancy
For the maintenance of pregnancy, the lifespan of the CL
must be extended. The question of whether this involves
further angiogenesis and increased vessel stabilization
requires to be investigated since failure of the CL due to a
malfunction of the vasculature could be a factor in miscar-
riage or infertility.
In the rodent, prolactin has a pivotal role. Prolactin secre-
tion induced by mating leads to increased endothelial cell
proliferation in the CL of pregnancy [36]. In prolactin
receptor deficient mice, CL angiogenesis is inhibited [37].
In the primate, the CL of pregnancy avoids luteolysis as a
result of 'rescue' by chorionic gonadotropin (CG) which
provides a major stimulus to prolong the function of the
hormone-producing cells. To investigate the question of
cellular and molecular changes in angiogenesis in primate
CL stimulated by CG, three sources have been employed:
1) ovaries from experimental animals in which timing of
conception has been determined, 2) CL from patients
with ectopic pregnancy 3) CLs from rhesus monkeys or
women following treatment in vivo with increasing doses
of hCG starting at the mid-luteal phase, to mimic the
endogenous stimulation of early pregnancy.
Following hCG treatment in rhesus monkeys there was no
associated burst of angiogenesis [10]. Similar conclusions
were reached from an early investigation after hCG treat-
ment in the human [11]. In marmosets, no increase in CL
angiogenesis was observed during early pregnancy [38].
This suggests that the vascular tree required for the CL of
pregnancy is already established during the normal luteal
phase.
A complication that may arise when analysing changes in
angiogenesis on luteal sections is that vascular density
may be influenced not only by angiogenesis but also by
changing volume of non-endothelial cells [1]. For exam-
ple, in the human CL there is an increase in luteal cell vol-
ume from early to mid-luteal phase and a decrease during
luteal regression which influences vascular density [1].
Expansion of granulosa lutein cell volume during luteal
rescue spreads proliferating endothelial cells further apart.
When changes in a particular cell content are quantified
per unit area of tissue, change in luteal cell volume (trans-
lated to area in tissue sections) has to be addressed, or
results will reflect the effects of expanding or contracting
tissue. When this was taken into account, hCG induced
luteal rescue was found to be associated with a significant
increase in endothelial cell content of the human CL [14].
This, taken with the fact that endothelial cell proliferation
increased at this stage, suggests that rescue of the human
corpus luteum is associated with an increased angiogenic
activity.
Early pregnancy may be associated with an increase in ves-
sel stability of the newly formed vasculature achieved by
recruitment of periendothelial support cells such as peri-
cytes. Rescue of the human corpus luteum is associated
with high pericyte coverage. Furthermore, it was shown
that the percentage of non-endothelial cell proliferation
(presumably pericytes) was highest during luteal rescue
[14].
Examination of whether similar changes occurred in early
pregnancy in the marmoset, showed that neither luteal
cell area, endothelial cell area, pericyte area or endothelial
cell proliferation differed from the mature CL of the non-
pregnant cycle [38]. It would appear that the mature luteal
vasculature of the non-pregnant marmoset is equipped
with the cellular components to perform the functions of
the vasculature of the CL of early pregnancy.
With respect to molecular changes in the rescued CL, it
appears that the production of those factors associated
with maintenance of the vasculature is continued under
the influence of hCG with Ang-1 acting to stabilise the
vessels, possibly by recruiting pericytes. In CL obtained at
6–8 weeks of pregnancy in women, VEGF mRNA was
higher than at mid-luteal phase [21]. VEGF mRNA quan-
tified by in situ hybridization [22] and VEGF immunos-
taining [14] increased after hCG-induced rescue.
However, no rise in Ang-1 mRNA was detected to explain
increase in pericytes [22]. Again, in the marmoset model,
none of these changes were observed [38].
Clearly, further investigation, especially in the human, is
required to determine the molecular regulation of the CL
of pregnancy.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/88
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Regression
Because the CL, including its vascular system, disappear
during structural luteolysis, it has been tempting to
believe that the programmed cell death associated with
apoptosis is the principal mechanism involved. A funda-
mental question is whether regression of the vasculature
plays a role in the functional and structural regression of
the surrounding hormone-producing cells. The most
compelling evidence for the involvement of luteal
endothelial cell apoptosis come from observations on the
regressing CL in the sheep [39] and guinea pig [40] in
which blood vessels become occluded with cellular
debris, presumably from endothelial cells. It was pro-
posed that this cascade would result in ischemia and
hypoxia leading to apoptosis of endothelial cells followed
by apoptosis of hormone-producing cells. A major diffi-
culty in determining the role of endothelial cell apoptosis
in luteolysis may be the fact that the timing of luteal
regression and the mechanisms which regulate it vary
between species. For example, the period the CL functions
by producing progesterone ranges from less than a day in
the rodent to 21 days in the marmoset [41-43]. Also, the
degenerative period can be very rapid (one cycle in the
hamster) to gradual (several cycles in rat and human)
[41,42]. In the hamster, the destruction of the CL between
days 2 and 3 of the 4 day cycle is associated with massive
apoptosis both of hormone-producing and endothelial
cells [41]. However, the initiation of apoptosis was not
apparent until several hours after the onset of the decline
in plasma progesterone (functional luteolysis). In the
human, a peak of apoptosis is found in regressing CL
observed in both the theca-lutein and granulosa-lutein
areas during the peri-menstrual period, from a few days
before to a few days after menstruation [42]. Similarly,
apoptosis peaked in CL of the early follicular phase in the
marmoset [43]. These, and other observations [44] sug-
gest that apoptosis is rarely observed in the primate CL
and is confined to a short time span. Apoptosis represents
an initial step in structural luteolysis, after which most
steroidogenic cells survive to undergo a process of gradual
involution [42]. The studies in the sheep showing a rapid
degeneration of blood vessels during luteolysis [39] may
be related to species such as the sheep, cow and horse in
which luteolysis is induced by prostaglandin which may
induce rapid changes in blood flow resulting in a luteo-
lytic cascade [45]. In primates, there is little evidence to
suggest that luteal vascular degeneration is a trigger for
luteolysis [46], but the onset of the former would
undoubtedly lead to a reduction in the supply of oxygen
and nutrients, and perhaps contribute to lutein cell death.
The availability of inhibitors of angiogenesis for in vivo
studies should provide a new approach to help elucidate
the relationship between regression of the vasculature and
functional and structural integrity of the hormone-pro-
ducing cells.
Manipulation of angiogenesis
Studies of angiogenic factors in the CL at various stages of
the cycle as described above provide useful pointers to
their physiological role in regulation of luteal angiogen-
esis. The next stage of investigation should involve specif-
ically inhibiting angiogenic factors in vivo using effects on
luteal angiogenesis as a indicator of effectiveness. A large
number of anti-angiogenic agents are being generated.
Antagonists developed specifically to target individual
angiogenic factors are the most useful, since specific fac-
tors may be targeted, their role established, and overall
controlling pathways unravelled. Striking results have
been obtained by inhibiting VEGF, either by specific VEGF
antibody [47], anti-VEGF receptor antibody [48], soluble
decoy receptors created by fusing the first three domains
of VEGFR-1 to the Fc portion of human IgG [49] or higher
affinity VEGF 'traps' also based upon the VEGF receptors
[50,51].
When soluble VEGFR-1 fusion protein was injected
directly into the pre-ovulatory follicle of rhesus monkeys
the day before or the day of the mid-cycle LH surge
decreased subsequent luteal progesterone in the serum,
while the length of the luteal phase was of normal dura-
tion [52]. However, treatment at this time did not effect
luteal angiogenesis or development of the microvascular
tree.
In marmosets, the intense angiogenesis in the early CL has
been targeted. In agreement with results which show that
LH/hCG stimulates VEGF production, suppressing endog-
enous LH by GnRH antagonist treatment commencing 1
day post-ovulation inhibits early luteal angiogenesis [9].
However, withdrawal of LH in vivo is likely to disrupt not
only VEGF but also the action a variety of luteal factors
and cell-cell interactions likely to be necessary for angio-
genesis and survival of hormone-producing cells.
Using treatment schedules at specific stages in the luteal
phase, the role of VEGF in luteal angiogenesis has been
examined in the marmoset [50,53-55]. VEGF inhibitors
have been administered in the following schedules: 1)
from day 0–3 or, 2) day 0–10 of the luteal phase, 3) luteal
day 3–4 or, 4) luteal days 7–10. Ovaries were studied at
the end of these treatment periods. Treatments 1 and 2,
commencing at or shortly after ovulation, targeted VEGF
during the period of intense luteal angiogenesis. The first
schedule was over a three-day period, so that the CL was
examined at a time of normal maximal proliferative activ-
ity. The second continued this treatment to the mid-luteal
phase, by which time the microvascular tree is established
in normal animals. The initial short-term treatment mark-
edly reduced the number of proliferating cells, while the
more prolonged treatment resulted in a change in the vas-
cular tree: the larger vessels were still present, but thereReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/88
Page 6 of 8
(page number not for citation purposes)
was a dearth of the numerous small capillaries found in
the normal CL [53]. CL function was inhibited as demon-
strated by a reduction in the concentrations of plasma
progesterone [53].
The third and fourth schedules addressed the issue of
whether inhibition of VEGF could intervene with on-
going angiogenesis. Treatment on day 3–4 [50] or 7–10
[54] resulted in a marked decrease in angiogenesis. Inter-
estingly, treatment at these times was associated with a fall
in plasma progesterone. Recent studies in which the more
potent VEGF trap R1R2 has been administered on days 7,
14 or 19 post ovulation show that functional luteolysis
results [55]. Such an effect would not be expected if the
treatment is acting by inhibiting angiogenesis alone.
Three possibilities arise. One is that treatment is suppress-
ing serum LH. Second, inhibition of VEGF is destroying
existing luteal blood vessels, or third, that ovarian perme-
ability is being compromised. It is possible to discount the
possibility that LH is decreased as studies of inhibition of
VEGF in macaques show LH to rise [48], presumably as a
result of withdrawal of negative feedback. Also, in contrast
to the situation observed for treatment with the GnRH
antagonist, the morphological features of the lutein cells
in the anti-VEGF animals remain essentially intact [53-
55]. There is an increase in endothelial cell death after
inhibition of VEGF at the mid-luteal phase, but it is not
extensive [54,55]. Thus, it would appear that ovarian per-
meability is being compromised such that either LDL-cho-
lesterol required for progesterone synthesis does not gain
entry into the cell or release of progesterone from the hor-
mone producing cells is restricted. This possibility
remains to be investigated.
Overall, these data demonstrate that inhibition of VEGF
during early luteal development prevents the intense ang-
iogenesis normally occurring at this time, leading to a fail-
ure of development of the microvascular tree. This in turn
has an adverse effect on the CL whose ability to secrete
progesterone is severely restricted. An additional factor
contributing to the fall in progesterone secretion after
inhibition of VEGF may be a suppression of ovarian
microvascular permeability.
With respect to the regulation of luteal activity in early
pregnancy, as reviewed above, the increase in angiogen-
esis in the human CL after hCG does not appear to occur
in the non-human primate model [38]. In view of the fact
that the period of intense luteal angiogenesis in the fertile
cycle of the marmoset is restricted to the early luteal phase
in the non-human primate, the effects of inhibiting VEGF
during this period were examined in marmosets in family
groups, in which pregnancy rate is over 80% [38]. We
used the same treatment schedule which inhibited angio-
genesis, prevented formation of the microvascular tree
and suppressed plasma progesterone in the normal cycle.
The results confirmed that the VEGF antibody markedly
suppressed plasma progesterone in the mated females.
However, after cessation of treatment 10 days post-ovula-
tion, a degree of recovery of progesterone secretion was
observed so that in 5 of the 10 treated marmosets, the CL
was subsequently successfully rescued. These animals
went on to deliver normal offspring at the same time as
the controls. The fact that pregnancy was successfully
established in the face of a marked reduction in plasma
progesterone concentrations suggests that in the marmo-
set, the normal quota of luteal progesterone is in excess of
requirement. Furthermore, the rise in plasma progester-
one post-treatment in half of the animals, implies that
angiogenesis is capable of re-initiation after cessation of
VEGF inhibition. Further studies are required to deter-
mine the outcome in other species and to determine
effects of the more potent VEGF traps.
Conclusions
Considerable progress has been made on describing the
cellular and molecular events associated with angiogen-
esis in the CL. Further work is needed to elucidate the
divergent changes seen in the vasculature during luteolysis
and rescue. The lack of clarity as to whether changes in the
vasculature precede luteolysis and to the cellular events
associated with early pregnancy may in part be the result
of species differences. The use of luteal angiogenesis as a
target for investigation of the physiological role of indi-
vidual angiogenic factors has fulfilled its promise. Inhibi-
tion of VEGF has a profound inhibitory effect upon luteal
function. The mechanism appears to involve suppression
of other functions, probably permeability, in addition to
inhibition of angiogenesis. These results may help shed
light on the phenomenon of luteal insufficiency and have
clinical relevance in our ability to manipulate luteal func-
tion. Finally, the observations made on inhibition of
VEGF should form a platform for deciphering the role of
other putative angiogenic regulators.
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